Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jul 29;6:288. doi: 10.1038/s41392-021-00712-2

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 3 — In vivo prophylactic and therapeutic efficacy of EK1 peptides against SARS-CoV-2 infection in hACE2 transgenic mouse models. a Schematic diagram of EK1 or EK1C4 administration and SARS-CoV-2 challenge. The mice in the treatment group were nasally administrated with a test peptide 30 min after challenge with SARS-CoV-2. The mice in the pre-treatment group and vehicle control group mice were nasally treated with a test peptide or vehicle control, respectively, 30 min before challenge with SARS-CoV-2. b Anti-SARS-CoV-2 efficacy of EK1 (200 μg/mouse) in hACE2 transgenic ICR mouse model. Viral titer in lung tissue of mice in each group on the 4th day of post-infection was detected. c, d Anti-SARS-CoV-2 efficacy of EK1 (200 μg/mouse) in vivo on hACE2 transgenic C57BL/6 mouse model. Viral titer in mouse lung (c) or intestine (d) of each group on the 4th day of post-infection was detected. e, f Anti-SARS-CoV-2 potency of EK1C4 (10 μg/mouse) in vivo on hACE2 transgenic C57BL/6 mouse model. Viral titer in lung (e) or intestine (f) of mice in each group on 4th day after SARS-CoV-2 challenge was detected. **P < 0.01, ***P < 0.001. g Histopathological examination of lung tissue of Tgtn(CAG-human ACE2-IRES-Luciferase) mice with or without administration of EK1 peptides. Lungs from hACE2 transgenic C57 mice were collected on the day 4 of post-infection. The lung tissue sections were stained with hematoxylin and eosin for histopathological examination. Scale bars in black, 200 μm (upper), scale bars in red, 40 μm (bottom)